Zhou et al. identified luteolin as a potential agent for alleviating BCP associated with lung cancer by targeting NLRP3 inflammasome and glial activation.42 Furthermore, the total alkaloids of Corydalis have been found to inhibit the RANKl-induced NF-κB and c-Fos/NFATc1 pathway, thereby mitigating the progression of BCP.43 In a similar vein, the current investigation demonstrated that LSW significantly elevated the pain threshold in rats, as indicated by enhanced PWT and PWL, while also reducing levels of inflammatory cytokines in the serum. The gene discussed is NLRP3; the disease is lung cancer.